| HOME >> BIOLOGY >> TECHNOLOGY |
Lorus Therapeutics Receives New Patent for LOR-2040, Leukemia
Drug II-55
Spectrum Pharmaceuticals Obtains Canadian Authorities Approval
for Phase III Clinical Trial of EOquin II-55
NCCN Obtains Grant to Evaluate Cetuximab Efficacy in Bladder
Cancer II-55
Allos Therapeutics Commences Phase II Trials for Pralatrexate II-56
Halozyme Announces Status Update of Chemophase® Phase I/IIa
Clinical Trial II-56
Spectrum Pharmaceuticals Establishes New Company in Canada II-56
China Medical Technologies Acquires FISH Business II-56
Peregrine Acquires Global License for Anti-Angiogenesis
Technology II-57
Bristol-Myers Terminates Partnership with Pierre Fabre II-57
9. FOCUS ON SELECT GLOBAL PLAYERS II-58
Affitech A/S (Denmark) II-58
Allergan, Inc. (USA) II-58
Allos Therapeutics, Inc. (USA) II-59
Astellas Pharma, Inc. (Japan) II-59
Astrazeneca Plc. (UK) II-59
AVI BioPharma, Inc. (USA) II-60
BioCancell Therapeutics, Inc. (Israel) II-60
Bioniche Life Sciences, Inc. (Canada) II-61
Bristol-Myers Squibb Company (USA) II-61
Celldex Therapeutics, Inc. (USA) II-62
Cytavis BioPharma GmbH (Germany) II-62
Eli Lilly and Company (USA) II-63
Endo Pharmaceuticals Holdings, Inc. (USA) II-63
ENKAM Pharmaceuticals A/S (Denmark) II-64
F. Hoffmann-La Roche Ltd. (Switzerland) II-64
Halozyme Therapeutics, Inc. (USA) II-64
Laboratoires Pierre Fabre SA (France) II-65
NatImmune A/S (Denmark) II-65
Oncogenex Pharmaceuticals, Inc. (USA) II-66
OncoTherapy Science, Inc. (Japan) II-66
Sanofi-Aventis (France) II-66
Spectrum Pharmaceuticals, Inc. (USA) II-67
Telormedix SA (Switzerland) II-67
Viventia Biotechnologies, Inc. (Canada) II-68
10. GLOBAL MARKET PERSPECTIVE II-69
Table 10: World Recent Past, Current &a
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |